APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health
Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...
336 Views
Myungin Pharmaceutical IPO Bookbuilding Analysis
Myungin Pharm's IPO price has been confirmed at 58,000 won, which is at the high end of the IPO price range. The demand ratio was 488.9 to 1.
347 Views
Myungin Pharmaceutical IPO Valuation Analysis
Our base case valuation of Myungin Pharm is target price of 80,349 won per share, which is 39% higher than the high end of the IPO price range.
1.6k Views
Myungin Pharmaceutical IPO Preview
Myungin Pharmaceutical is getting ready to complete its IPO in KOSPI in September. The IPO price range is from 45,000 won to 58,000 won.
420 Views
EQD | KOSPI 200 May Pullback Soon...
Pullbacks on the KOSPI 200 INDEX are currently a buy opportunity, given the short-selling ban still in place. We predict a short-term WEEKLY...
320 Views